DUBLIN, Feb. 3, 2016 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/vkqjh2/global_gerd) has announced the addition of the "Global GERD Market 2016-2020" report to their offering.

The report forecast that the global GERD drugs market will grow at a CAGR of 2.85% during the period 2016-2020.

Awareness among individuals about GERD is increasing, and there are various therapies available for its treatment. This would increase the number of treatment-seeking patients, thus giving rise to the overall consumption of related drugs. Similarly, strategic alliances among vendors to consolidate their positions in the market are also expected to exert a positive influence on the market during the forecast period.

According to the report, the global GERD drugs market is driven the presence of huge unmet medical need in GERD. The lack of FDA approved drugs and the usage of generics and off-label drugs are causing market share erosion of prescription products. Thus, for drug makers, this presents an opportunity to develop therapies that can give them an edge over others to grab a major share of the total GERD drugs market.

Further, the report states that the use of complementary and alternative treatments by patients is a major challenge for the global GERD drugs market.

Key vendors:

• AstraZeneca
• Eisai
• GlaxoSmithKline
• Johnson & Johnson
• Takeda

Other prominent vendors:

• Ahn-Gook Pharmaceutical
• Cancer Advances
• CJ Cheil Jedang
• Daewoong Pharmaceutical
• Ironwood Pharmaceuticals
• RaQualia Pharma
• SFJ Pharmaceuticals Group
• Sucampo Pharmaceuticals
• Vecta Pharmaceuticals
• Wockhardt
• Yuhan
• Zeria Pharmaceutical

Key questions answered in this report:

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Key Topics Covered:

PART 01: Executive summary 

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Disease overview

PART 06: Pipeline portfolio

PART 07: Market landscape

PART 08: Market segmentation by drug class

PART 09: Global antacids market

PART 10: Global PPI drugs market

PART 11: Global H2 receptor antagonist drugs market

PART 12: Market segmentation by route of administration38

PART 13: Market segmentation by dosage form

PART 14: Geographical segmentation

PART 15: Market drivers

PART 16: Impact of drivers

PART 17: Market challenges

PART 18: Impact of drivers and challenges

PART 19: Market trends

PART 20: Vendor landscape

PART 21: Key vendor analysis

For more information visit http://www.researchandmarkets.com/research/vkqjh2/global_gerd

Media Contact:

Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets